Dena DeMarco

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings, Rogier Mous, Michael Roost Clausen et al. · The Lancet · 2021 · 337 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings, Rogier Mous, Michael Roost Clausen et al. · Blood · 2020 · 64 citations

Medicine, Oncology, Pharmacotherapy +17

Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With <scp>B‐Cell</scp> Lymphomas

Tommy Li, Ida H. Hiemstra, Christopher Chiu et al. · Clinical Pharmacology & Therapeutics · 2022 · 32 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.

Martin Hutchings, Pieternella J. Lugtenburg, Rogier Mous et al. · Journal of Clinical Oncology · 2020 · 23 citations

Medicine, Oncology, Pharmacotherapy +14

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella J. Lugtenburg, Rogier Mous, Michael Roost Clausen et al. · Blood · 2019 · 19 citations

Medicine, Immunology, Oncology +13